<rdf:RDF xmlns:api="http://www.elsevier.com/xml/svapi/rdf/dtd/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84893658088"><dc:identifier>https://api.elsevier.com/content/abstract/eid/2-s2.0-84893658088</dc:identifier><api:scopusId>84893658088</api:scopusId><api:eid>2-s2.0-84893658088</api:eid><api:pui>372334230</api:pui><prism:doi>10.1155/2014/731806</prism:doi><dc:title>Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus</dc:title><prism:issn>20900430</prism:issn><prism:contentType>Abstract</prism:contentType><prism:aggregationType>Journal</prism:aggregationType><api:srctype>j</api:srctype><api:subtype>ar</api:subtype><api:subtypeDescription>Article</api:subtypeDescription><api:citedbyCount>5</api:citedbyCount><api:articleNumber>731806</api:articleNumber><prism:publicationName>Autoimmune Diseases</prism:publicationName><api:sourceId>21100223559</api:sourceId><prism:volume>2014</prism:volume><prism:coverDate>2014-02-14</prism:coverDate><prism:copyrightYear>2014</prism:copyrightYear><api:openaccess>1</api:openaccess><api:openaccessFlag>true</api:openaccessFlag><dc:creator><rdf:Seq><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/55338538300"><api:authid>55338538300</api:authid><api:surname>Bonilla-Abadía</api:surname><api:givenName>Fabio</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60104957"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/56030723700"><api:authid>56030723700</api:authid><api:surname>Coronel Restrepo</api:surname><api:givenName>Nicolás</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60109272"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/8593115600"><api:authid>8593115600</api:authid><api:surname>Tobón</api:surname><api:givenName>Gabriel J.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60104957"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/36833478300"><api:authid>36833478300</api:authid><api:surname>Echeverri</api:surname><api:givenName>Andrés F.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60104957"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/55530959500"><api:authid>55530959500</api:authid><api:surname>Muñoz-Buitrón</api:surname><api:givenName>Evelyn</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60109272"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/56029296000"><api:authid>56029296000</api:authid><api:surname>Castro</api:surname><api:givenName>Andres Mauricio</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60109272"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/56029932400"><api:authid>56029932400</api:authid><api:surname>Bejarano</api:surname><api:givenName>Mercedes Andrade</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60066812"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/6602513913"><api:authid>6602513913</api:authid><api:surname>Cañas</api:surname><api:givenName>Carlos A.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60104957"/></api:Author></rdf:li></rdf:Seq></dc:creator><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2723"/><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2403"/><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2401"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0141891339"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/82555196095"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/74449091545"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/38749089852"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874374884"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84866022273"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/77954651554"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/77954632414"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/74849131972"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84866184129"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/80053647500"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/79952196706"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0020436689"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33750720650"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0026777352"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84893697206"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/47049098355"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/67349227965"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/78650416364"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84868012506"/><api:scopusPage rdf:resource="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84893658088&amp;origin=inward"/></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60104957"><api:afid>60104957</api:afid><skos:prefLabel>Universidad Icesi</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60109272"><api:afid>60109272</api:afid><skos:prefLabel>Fundacion Valle del Lili</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60109272"><api:afid>60109272</api:afid><skos:prefLabel>Fundacion Valle del Lili</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60066812"><api:afid>60066812</api:afid><skos:prefLabel>Universidad del Valle</skos:prefLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2723"><api:code>2723</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Immunology and Allergy</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2403"><api:code>2403</api:code><api:abbrev>IMMU</api:abbrev><skos:prefLabel>Immunology</skos:prefLabel><skos:altLabel>Immunology and Microbiology</skos:altLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2401"><api:code>2401</api:code><api:abbrev>IMMU</api:abbrev><skos:prefLabel>Immunology and Microbiology (miscellaneous)</skos:prefLabel><skos:altLabel>Immunology and Microbiology</skos:altLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0141891339"><api:scopusId>0141891339</api:scopusId><dc:title>Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1.000 patients</dc:title><prism:publicationName>Medicine</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>82</prism:volume><prism:startingPage>299</prism:startingPage><prism:endingPage>308</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/82555196095"><api:scopusId>82555196095</api:scopusId><dc:title>Mechanisms of disease: Systemic lupus erythematosus</dc:title><prism:publicationName>The New England Journal of Medicine</prism:publicationName><prism:publicationYear>2011</prism:publicationYear><prism:volume>365</prism:volume><prism:startingPage>2110</prism:startingPage><prism:endingPage>2121</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/74449091545"><api:scopusId>74449091545</api:scopusId><dc:title>Unde rsta nding the epidemiology a nd progression of s ys temic lupus erythematosus</dc:title><prism:publicationName>Seminars in Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>39</prism:volume><prism:startingPage>257</prism:startingPage><prism:endingPage>268</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/38749089852"><api:scopusId>38749089852</api:scopusId><dc:title>EULAR recommendations for the management of SLE</dc:title><prism:publicationName>Annals of the Rheumatic Diseases</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>67</prism:volume><prism:startingPage>195</prism:startingPage><prism:endingPage>205</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874374884"><api:scopusId>84874374884</api:scopusId><dc:title>Belimumab: Targeted therapy for lupus</dc:title><prism:publicationName>International Journal of Rheumatic Diseases</prism:publicationName><prism:publicationYear>2013</prism:publicationYear><prism:volume>16</prism:volume><prism:startingPage>4</prism:startingPage><prism:endingPage>13</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84866022273"><api:scopusId>84866022273</api:scopusId><dc:title>Efficacy and safety of rituximab therapy for systemic lupus erythematosus: A systematic review and meta-analysis</dc:title><prism:publicationName>Journal of Zhejiang University-Science B</prism:publicationName><prism:publicationYear>2012</prism:publicationYear><prism:volume>13</prism:volume><prism:startingPage>731</prism:startingPage><prism:endingPage>744</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/77954651554"><api:scopusId>77954651554</api:scopusId><dc:title>Rituximab versus cyclophosphamide for ANCA-associated vasculitis</dc:title><prism:publicationName>The New England Journal of Medicine</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>363</prism:volume><prism:startingPage>221</prism:startingPage><prism:endingPage>232</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/77954632414"><api:scopusId>77954632414</api:scopusId><dc:title>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis</dc:title><prism:publicationName>The New England Journal of Medicine</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>363</prism:volume><prism:startingPage>211</prism:startingPage><prism:endingPage>220</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/74849131972"><api:scopusId>74849131972</api:scopusId><dc:title>Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>62</prism:volume><prism:startingPage>222</prism:startingPage><prism:endingPage>233</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84866184129"><api:scopusId>84866184129</api:scopusId><dc:title>Efficacy and safety of rituximab in patients with active proliferative lup us nephritis: The lup us nep hritis assessme nt with rituximab study</dc:title><prism:publicationName>Arthritis &amp; Rheumatism</prism:publicationName><prism:publicationYear>2012</prism:publicationYear><prism:volume>64</prism:volume><prism:startingPage>1215</prism:startingPage><prism:endingPage>1226</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/80053647500"><api:scopusId>80053647500</api:scopusId><dc:title>Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>2011</prism:publicationYear><prism:volume>20</prism:volume><prism:startingPage>1219</prism:startingPage><prism:endingPage>1226</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/79952196706"><api:scopusId>79952196706</api:scopusId><dc:title>Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus</dc:title><prism:publicationName>Nephrology, Dialysis, Transplantation</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>25</prism:volume><prism:startingPage>3586</prism:startingPage><prism:endingPage>3592</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0020436689"><api:scopusId>0020436689</api:scopusId><dc:title>The 1982 revised criteria for the classification of systemic lupus erythrematosus</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>1982</prism:publicationYear><prism:volume>25</prism:volume><prism:startingPage>1271</prism:startingPage><prism:endingPage>1277</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33750720650"><api:scopusId>33750720650</api:scopusId><dc:title>Assessing remission in systemic lupus erythematosus</dc:title><prism:publicationName>Clinical and Experimental Rheumatology</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>24</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0026777352"><api:scopusId>0026777352</api:scopusId><dc:title>Derivation of the SLEDAI: A disease activity index for lupus patients</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>1992</prism:publicationYear><prism:volume>35</prism:volume><prism:startingPage>630</prism:startingPage><prism:endingPage>640</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84893697206"><api:scopusId>84893697206</api:scopusId><dc:title>Successful desensitizationtorituximab in four patients with autoinmune diseases</dc:title><prism:publicationName>Proceedings of the EAACI-WAO Congress</prism:publicationName><prism:publicationYear>2013</prism:publicationYear></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/47049098355"><api:scopusId>47049098355</api:scopusId><dc:title>Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?</dc:title><prism:publicationName>Clinical Reviews in Allergy and Immunology</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>34</prism:volume><prism:startingPage>124</prism:startingPage><prism:endingPage>128</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/67349227965"><api:scopusId>67349227965</api:scopusId><dc:title>B-cell depletion in autoimmune diseases. Advances in autoimmunity</dc:title><prism:publicationName>Autoimmunity Reviews</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>8</prism:volume><prism:startingPage>585</prism:startingPage><prism:endingPage>590</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/78650416364"><api:scopusId>78650416364</api:scopusId><dc:title>The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus</dc:title><prism:publicationName>Autoimmunity Reviews</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>10</prism:volume><prism:startingPage>108</prism:startingPage><prism:endingPage>111</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84868012506"><api:scopusId>84868012506</api:scopusId><dc:title>Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten year experience at asingle center</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2012</prism:publicationYear><prism:volume>64</prism:volume><prism:startingPage>3770</prism:startingPage><prism:endingPage>3778</prism:endingPage></rdf:Description></rdf:RDF>